Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679959 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
A Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 1
- Study location
NCT06679959: Active Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
NCT06679959 is a Phase 1 study of Chronic Weight Management that is active but no longer recruiting, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 115 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679959, a Phase 1 study of Chronic Weight Management, is active but no longer recruiting, sponsored by Ascletis Pharma (China) Co., Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Primary Outcome
A summary of AEs, SAEs and other non-serious adverse events
Conditions Studied
Interventions
- DRUG ASC30 Injection, for subcutaneous use or placebo
Study Locations (1)
Texas
- Ascletis clinical site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What the registry record for NCT06679959 still lists
NCT06679959 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Chronic Weight Management appearing as the primary indexed condition, and to 1 intervention - of which ASC30 Injection, for subcutaneous use or placebo is the first listed.
NCT06679959 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06679959 about?
NCT06679959 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity". This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
What is the current status of trial NCT06679959?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-09-16. Estimated completion is 2026-04.
What conditions does trial NCT06679959 study?
This clinical trial studies the following conditions: Chronic Weight Management.
What interventions are being tested in trial NCT06679959?
The interventions under investigation include: ASC30 Injection, for subcutaneous use or placebo (DRUG).
Who is sponsoring clinical trial NCT06679959?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679959 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679959's enrollment target sits among peer trials
115 504th of 2000 higher than 1,494 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
COMPLETED · Phase 1
-
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI